Successful use of next generation genomic sequencing (NGS)-directed therapy of clear cell carcinoma of the ovary (CCCO) with trametinib and metformin in a patient with chemotherapy-refractory disease

Table 1 FoundationOne™ genomic testing identified three driver mutations, of which two were actionable with available drugs

Therapeutic Implications
Genomic Alteration	FDA-approved therapies for ovarian cancer	FDA-approved therapies for other tumor types
KRAS	None	Trametinib
G12v
PIK3CA	None	Everolimus, temsirolimus
H1047R
TERT	None	None
Promoter 124 C > T

ISSN: 2053-6844